CAS Number: 656247-17-5

Stage: Pipeline

Nintedanib is a tyrosine kinase inhibitor (TKI) approved for the treatment of idiopathic pulmonary fibrosis (IPF) and various forms of progressive fibrosing interstitial lung diseases (PF-ILDs). It is also used in non-small cell lung cancer (NSCLC). By targeting multiple pathways involved in fibrosis and angiogenesis, Nintedanib slows disease progression and improves lung function outcomes. Explore Royal Pharma as your potential partner for Nintedanib API.